These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24103752)

  • 41. Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.
    Ashutosh ; Garg M; Sundar S; Duncan R; Nakhasi HL; Goyal N
    Antimicrob Agents Chemother; 2012 Jan; 56(1):518-25. PubMed ID: 22064540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
    Thakur CP; Dedet JP; Narain S; Pratlong F
    Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio.
    Haldar AK; Banerjee S; Naskar K; Kalita D; Islam NS; Roy S
    Exp Parasitol; 2009 Jun; 122(2):145-54. PubMed ID: 19422069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
    Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leishmania donovani: genetic diversity of isolates from Sudan characterized by PCR-based RAPD.
    Hamad SH; Khalil EA; Musa AM; Ibrahim ME; Younis BM; Elfaki ME; El-Hassan AM;
    Exp Parasitol; 2010 Aug; 125(4):389-93. PubMed ID: 20346944
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent.
    Dumetz F; Cuypers B; Imamura H; Zander D; D'Haenens E; Maes I; Domagalska MA; Clos J; Dujardin JC; De Muylder G
    mSphere; 2018 Apr; 3(2):. PubMed ID: 29669889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential expression of proteins in antimony-susceptible and -resistant isolates of Leishmania donovani.
    Biyani N; Singh AK; Mandal S; Chawla B; Madhubala R
    Mol Biochem Parasitol; 2011 Oct; 179(2):91-9. PubMed ID: 21736901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
    Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
    Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
    Escobar P; Yardley V; Croft SL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani.
    Purkait B; Kumar A; Nandi N; Sardar AH; Das S; Kumar S; Pandey K; Ravidas V; Kumar M; De T; Singh D; Das P
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1031-41. PubMed ID: 22123699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.
    Roychoudhury J; Sinha R; Ali N
    PLoS One; 2011 Mar; 6(3):e17376. PubMed ID: 21423750
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic markers for antimony resistant clinical isolates differentiation from Indian Kala-azar.
    Khanra S; Sarraf NR; Das S; Das AK; Roy S; Manna M
    Acta Trop; 2016 Dec; 164():177-184. PubMed ID: 27629023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.
    Pal S; Ravindran R; Ali N
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genomic insights into virulence mechanisms of Leishmania donovani: evidence from an atypical strain.
    Samarasinghe SR; Samaranayake N; Kariyawasam UL; Siriwardana YD; Imamura H; Karunaweera ND
    BMC Genomics; 2018 Nov; 19(1):843. PubMed ID: 30486770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani.
    Kumar A; Sisodia B; Misra P; Sundar S; Shasany AK; Dube A
    Br J Clin Pharmacol; 2010 Oct; 70(4):609-17. PubMed ID: 20840452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Remarks on identification of amplified fragment length polymorphisms linked to SAG resistance in Leishmania.
    Van der Auwera G; Bhattarai NR; Odiwuor S; Vuylsteke M
    Acta Trop; 2010 Jan; 113(1):92-3. PubMed ID: 19800857
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC; Mullen AB; Sundar S; Kenney RT
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leishmania donovani: assessment of leishmanicidal effects of herbal extracts obtained from plants in the visceral leishmaniasis endemic area of Bihar, India.
    Singh SK; Bimal S; Narayan S; Jee C; Bimal D; Das P; Bimal R
    Exp Parasitol; 2011 Feb; 127(2):552-8. PubMed ID: 21070771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal.
    Laurent T; Rijal S; Yardley V; Croft S; De Doncker S; Decuypere S; Khanal B; Singh R; Schönian G; Kuhls K; Chappuis F; Dujardin JC
    Infect Genet Evol; 2007 Mar; 7(2):206-12. PubMed ID: 17010679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
    Mishra J; Madhubala R; Singh S
    Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.